Background: The introduction of HIV-1 protease inhibitors into the treatment of patients infected with HIV-1 has had a major influence on clinical practice. However, the use of protease inhibitors is frequently associated with the development of resistance and several side effects and interactions with other drugs have been reported. Observations: We present the first pediatric patient with paronychia with pyogenic granuloma associated with the administration of the protease inhibitor indinavir. Clinical findings are discussed in view of a possible interference of indinavir with endogenous retinoid metabolism. Conclusion: Considerable evidence advocates the mediation of indinavir side effects by impaired oxidative metabolism of retinoic acid through the inhibition of cytochromes P450 3A by indinavir rather than by impaired formation of 9-cis-retinoic acid.

Deeks SG, Smith M, Holodniy M, Kahn JO: HIV-1 protease inhibitors – A review for clinicians. JAMA 1997;277:145–153.
Carr A, Samaras K, Chisholm DJ, Cooper DA: Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351:1881–1883.
Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA: Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet 1999;353:2093–2099.
Bouscarat F, Bouchard C, Bouhour D: Paronychia and pyogenic granuloma of the great toes in patients treated with indinavir. N Engl J Med 1998;338:1776–1777.
Tosti A, Piraccini BM, D’Antuono A, Marzaduri S, Bettoli V: Paronychia associated with antiretroviral therapy. Br J Dermatol 1999;140: 1165–1168.
Bourezane Y, Thalamy B, Viel JF, Bardonnet K, Gil H, Drobacheff C, Vuitton DA, Hoen B: Ingrown toenails and indinavir: Case-control study demonstrates strong relationship (abstract/poster 681). 6th Conf Retroviruses Opportunistic Infect, Chicago, February 1999.
Sarcletti M, Petter A, Zangerle R: Indinavir and interstitial nephritis. Ann Intern Med 1998; 124:320–321.
Baran R: Etretinate and the nails (study of 130 cases) – Possible mechanisms of some side-effects. Clin Exp Dermatol 1986;11:148–152.
Traupe H, Happle R: Etretinate therapy in children with severe keratinization defects. Eur J Pediatr 1985;143:166–169.
Blumental G: Paronychia and pyogenic granuloma-like lesions with isotretinoin. J Am Acad Dermatol 1984;10:677–678.
De Raeve L, Willemsen M, De Coninck A, Roseeuw D: Paronychie et formation de tissu granuleux au cours d’un traitement par isotrétinoïne. Dermatologica 1986;172:278–280.
Geiger J-M, Czarnetzki BM: Acitretin (Ro 10-1670, Etretin): Overall evaluation of clinical studies. Dermatologica 1988;176:182–190.
Lenhard JM, Weiel JE, Paulik MA, Lehmann JM, Koszalka G, Furfine ES: Indinavir enhances retinoic acid signalling: Nelfinavir, saquinavir, and ritonavir inhibit retinoid effects in vitro (abstract/poster 665). 6th Conf Retroviruses Opportunistic Infect, Chicago, February 1999.
Napoli JL: Retinoic acid biosynthesis and metabolism. FASEB J 1996;10:993–1001.
Lanvers C, Hempel G, Blaschle G, Boos J: Chemically induced isomerization and differential uptake modulate retinoic acid disposition in HL-60 cells. FASEB J 1998;12:1627–1633.
van Wauwe JP, Coene MC, Goossens J, Cools W, Monbaliu J: Effects of cytochrome P-450 inhibitors on the in vivo metabolism of all-trans-retinoic acid in rats. J Pharmacol Exp Ther 1990;252:365–369.
Martini R, Murray M: Participation of P450 A enzymes in rat hepatic microsomal retinoic acid 4-hydroxylation. Arch Biochem Biophys 1993; 303:57–66.
Gagnon AM, Angel JB, Sorisky A: Protease inhibitors and adipocyte differentiation in cell culture. Lancet 1998;352:1032.
Leid M, Kastner P, Chambon P: Multiplicity generates diversity in the retinoic acid signalling pathways. Trends Biochem Sci 1992; 17:427–433.
Peck GL, DiGiovanna J: Synthetic retinoids in dermatology; in Sporn MB, Roberts AB, Goddman DS (eds): The Retinoids: Biology, Chemistry, and Medicine, ed 2. New York, Raven Press, 1994, pp 631–658.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.